Certara, Inc. (NASDAQ: CERT)

Certara, Inc., a leading provider of biosimulation technology and solutions, operates under the ticker symbol CERT in the pharmaceutical industry. The company's main business activities include developing and providing biosimulation software and technology-enabled services that help pharmaceutical companies make better decisions during the drug development process. Certara's offerings are particularly valuable in the highly regulated and competitive pharmaceutical sector, where efficient decision-making can significantly impact a company's success.

The company's primary products and services include Simcyp Simulator, a mechanistic biosimulation platform for physiologically-based pharmacokinetic simulation; Phoenix, a software platform for managing, analyzing, and reporting pharmacokinetic, pharmacodynamic, and toxicokinetic data; Pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; and CoAuthor, a structured content authoring tool that utilizes Certara.AI to generate content for regulatory submissions preparation and medical writing. These solutions cater to life sciences companies of all sizes, contract research organizations, academic institutions, and global regulators.

With a large and growing customer base, Certara's software and services have been used by nearly 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies by R&D spend in 2022. This widespread adoption demonstrates the company's strong position within the industry, fueled by its reputation for delivering high-quality products and services.

Certara's expertise in biosimulation and its ability to provide end-to-end solutions for the drug development process set it apart from competitors such as Mathworks, Ansys, Simulations plus, and NONMEM, a division of ICON. Additionally, Certara's technology-enabled services compete with in-house teams at biopharmaceutical companies and specialized service providers such as Metrum Research, qPharmetra, and Pharmetheus.

The company's technology-enabled services and software are used to support a wide range of activities, including drug discovery, development, and commercialization, as well as the preparation of regulatory submissions, clinical trial reports, pharmacokinetic and pharmacodynamic analysis, and labeling and packaging design. Certara's regulatory science solutions support submissions to global health agencies, including the US FDA, the European Medicines Agency, and the Japanese Pharmaceuticals and Medical Devices Agency.

Certara's growth strategy focuses on building upon its existing platforms, creating more value through increased automation and connectivity, and expanding its customer base globally. The company is also investing in research and development to advance its biosimulation technology and develop new products and services.

Certara's human capital consists of a globally diverse team of scientists, software developers, and subject matter experts. As of December 31, 2023, the company employed 1,391 professionals in 28 countries, including 1,338 full-time employees and 53 part-time employees, of which 433 held PhDs in their respective disciplines.

To maintain its competitive edge, Certara safeguards its intellectual property through a full array of intellectual property rights, including copyrights, trade secrets, patents, tradenames, and trademarks. The company has implemented a multi-disciplinary privacy management program, technological safeguards, employee trainings, and policies to ensure compliance with privacy and cybersecurity laws, as well as anti-bribery laws such as the FCPA and the Bribery Act.